- Born to FriendsApril 14, 2016 | Paul Moss, PhD
Dr. Moss reviews the often-raised question of how we select a donor for a patient who needs a stem cell transplant and the three main options, which include an HLA-matched unrelated donor (URD), umbilical cord blood transplantation, or a haploidentical donor (HD).
- MRD Detection Testing to Study Clonal Selection and Drug ResistanceApril 14, 2016
Dr. O'Donnell and Dr. Raje look at a study that attempts to understand the biology of clonal plasma cells in low levels or MRD states after induction therapy, which can lead to a better understanding of chemoresistance and more effective therapies for MM.
- Novel Role for Iron Transport in Immune Cell FunctionApril 08, 2016 | Theresa Coetzer, PhD
Dr. Coetzer reviews a study that looks at the molecular defect in a subset of CID patients and resulting enhanced expression of TfR1 on lymphocytes, which has clinical relevance as it could be a useful diagnostic tool.
- Acute Myeloid Leukemia Minimal Residual Disease Comes of AgeApril 07, 2016
Dr. George and Dr. Chabot-Richards discuss a study that shows the different roles of NPM1 mutation in risk stratification and MRD monitoring in AML.
- BCL-2 Is an Effective Target in Chronic Lymphocytic LeukemiaApril 07, 2016 | Ann S. LaCasce, MD, MSc
Dr. LaCasce discusses the use of BLC2 as an effective therapy for patients with CLL, including those with poor risk features.
- Elegant Biology: Glycine- and Folate-correctable SLC25A38-mutated Sideroblastic AnemiaApril 07, 2016 | Sioban Keel, MD
Dr. Keel covers an approach to treating congenital sideroblastic anemia caused by SLC25A38 deficiency with glycine and folic acid supplementation.
- Caplacizumab for TTP: A Temporizing Measure for a Relapsing DiseaseMarch 25, 2016 | Adam Cuker, MD, MS
Dr. Cuker evaluates caplacizumab as a treatment for the relapse of patients with acquired thrombotic thrombocytopenic purpura (TTP).
- Corticosteroids for ITP: A Comparison of Two ApproachesMarch 25, 2016 | David Garcia, MD
Dr. Garcia discusses two approaches to the use of corticosteroids for the treatment of immune thrombocytopenia.
- Taking Advantage of the Collateral Damage of Cancer-Causing Mutations: MTAP Deletions Sensitize Cancer Cells to PRMT5 InhibitionMarch 25, 2016
Dr. Abdel-Wahab and Dr. Taylor shed light on two recent studies that have identified synthetic lethal interactions created by deletion of genes in the neighboring genome around the 9p21 locus. Deletion of the 9p21 locus is one of the most common genetic events in cancer, yet there is no therapy that targets cancer cells with this alteration.